Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Tyra Biosciences, Inc.NASDAQ: TYRA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $33.33M rose 33.5% year over year, ahead of the +26.9% change in trailing-twelve-month research & development. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +33.8% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +33.5% holds above the trailing-twelve-month pace of +26.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 102.93M USD
- Year-over-year change
- +28.5%
- 4-year CAGR
- +49.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 102.93M | +28.5% |
| FY2024 | 2024-12-31 | 80.08M | +28.1% |
| FY2023 | 2023-12-31 | 62.52M | +45.4% |
| FY2022 | 2022-12-31 | 43.01M | +108.4% |
| FY2021 | 2021-12-31 | 20.64M | — |
Research & Development vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 research & development of $111.3M is the 9th highest of the 11 companies compared; the peer median is $128.25M.
- Its year-over-year change of +26.9% is the 5th highest of 11, against a peer median of +20.3%.
- Over three fiscal years its annual growth of +33.8% compares with a peer median of +29.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $260.36M | +37.3% | +39.3% | 363.4% | |
| LTM Mar 2026 | $188.07M | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $127.65M | +60.8% | +33.1% | 590.6% | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $111.3M | +26.9% | +33.8% | — | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $111.11M | +29.3% | +58.7% | — |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| Peer median (excluding TYRA) | $128.25M | +20.3% | +29.1% | 270.1% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Selling, General & Admin | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| Operating Expenses | 26.29M | 58.93M | 79.95M | 104.18M | 132.76M |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| EBITDA | (26.15M) | (55.03M) | (68.78M) | (85.96M) | (119.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (26.29M) | (58.93M) | (79.95M) | (104.18M) | (132.76M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 3.65M | 10.81M | 17.7M | 12.82M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6K) | 3.6M | 10.81M | 17.7M | 12.82M |
| Income Before Tax | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| EPS (Diluted) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| Weighted Avg Shares | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Weighted Avg Shares (Diluted) | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.